cyclohexanol has been researched along with Obesity in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, XF; South, T | 1 |
| Brown, L; Eliasziw, M; Lavorato, DH; McLaren, L; Patten, SB; Williams, JV | 1 |
| Abood, ME; Bai, Y; Barak, LS; Caron, MG; Kapur, A; Sharir, H; Zhao, P | 1 |
| Berrendero, F; Burokas, A; Gispert, JD; Heyne, A; Kiesselbach, C; Maldonado, R; Martín, M; Martín-García, E; Millán, O; Rubí, B | 1 |
| Brusman-Lovins, L; King, KH; Malhotra, S; McElroy, SL; Welge, JA | 1 |
| Arguisola, MS; Tavakoli, SA | 1 |
| Barbiroli, B; Bernardi, F; Cicognani, A; Lin, L; Lodi, R; Mignot, E; Montagna, P; Parmeggiani, A; Plazzi, G; Posar, A; Scano, MC; Tonon, C | 1 |
| Feng, Y; Fong, TM; Francis, B; Goulet, MT; Guan, XM; Hagmann, WK; Jewell, JP; Lanza, TJ; Lao, J; Lin, LS; Liu, P; MacIntyre, DE; Marsh, DJ; Qi, H; Rosko, KM; Shah, SK; Shearman, LP; Shen, CP; Strack, AM; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J; Xiao, JC; Xu, SS; Yu, H | 1 |
| Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P | 1 |
| Ikeda, H; Odaka, H | 1 |
| Hayaishi, R; Imano, E; Kanda, T; Wada, M | 1 |
| Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM | 1 |
| Anghelescu, I; Himmerich, H; Klawe, C; Szegedi, A | 1 |
| Krause, HP; Puls, W | 1 |
| Ikeda, H; Matsuo, T; Odaka, H; Shino, A | 1 |
| Ikeda, H; Matsuo, T; Odaka, H | 1 |
| Fujioka, S; Keno, Y; Kobatake, T; Matsuzawa, Y; Tarui, S; Tokunaga, K | 1 |
| Fujioka, S; Inui, Y; Kawamoto, T; Keno, Y; Kobatake, T; Matsuo, T; Matsuzawa, Y; Odaka, H; Tarui, S; Tokunaga, K | 1 |
| Fujioka, S; Inui, Y; Kawata, S; Kobatake, T; Matsuzawa, Y; Minami, Y; Tamura, S; Tarui, S; Tokunaga, K | 1 |
1 trial(s) available for cyclohexanol and Obesity
| Article | Year |
|---|---|
Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Weight; Bulimia; Comorbidity; Cyclohexanols; Female; Humans; Middle Aged; Obesity; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
18 other study(ies) available for cyclohexanol and Obesity
| Article | Year |
|---|---|
Temporal and site-specific brain alterations in CB1 receptor binding in high fat diet-induced obesity in C57Bl/6 mice.
Topics: Animals; Body Weight; Brain; Cannabinoids; Cyclohexanols; Diet; Dietary Fats; Energy Intake; Humans; Leptin; Male; Mice; Mice, Inbred C57BL; Obesity; Receptor, Cannabinoid, CB1 | 2008 |
Major depression, antidepressant medication and the risk of obesity.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Incidence; Male; Middle Aged; Obesity; Risk Factors; Venlafaxine Hydrochloride; Young Adult | 2009 |
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Topics: Analgesics; Arrestins; beta-Arrestins; Cannabinoid Receptor Agonists; Cannabinoids; Cell Line; Cyclohexanols; Humans; Ligands; Lysophospholipids; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Obesity; Phosphorylation; Piperidines; Protein Kinase C; Protein Kinase C beta; Pyrazoles; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; Rimonabant | 2009 |
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Topics: Amides; Analysis of Variance; Animals; Autoradiography; Benzoxazines; Body Weight; Brain; Cyclohexanols; Diet Fads; Disease Models, Animal; Eating; Female; Guanosine 5'-O-(3-Thiotriphosphate); International Cooperation; Morpholines; Naphthalenes; Obesity; Piperidines; Protein Binding; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Isotopes; Time Factors; Tomography Scanners, X-Ray Computed; Tritium; Whole Body Imaging | 2010 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cyclohexanols; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Interactions; Drug Therapy, Combination; Humans; Male; Obesity; Olanzapine; Pirenzepine; Risk Factors; Valproic Acid; Venlafaxine Hydrochloride | 2003 |
Narcolepsy-cataplexy associated with precocious puberty.
Topics: Aspartic Acid; Benzhydryl Compounds; Cataplexy; Child; Creatine; Cyclohexanols; Disorders of Excessive Somnolence; Female; Hallucinations; Health Education; Humans; Hypothalamus; Intracellular Signaling Peptides and Proteins; Male; Modafinil; Narcolepsy; Neuropeptides; Night Terrors; Obesity; Orexins; Polysomnography; Puberty, Precocious; Television; Venlafaxine Hydrochloride | 2006 |
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Topics: Amides; Animals; Anti-Obesity Agents; Binding, Competitive; Body Temperature; Body Weight; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; Cyclohexanols; Dose-Response Relationship, Drug; Eating; Humans; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Obesity; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Transfection | 2007 |
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2008 |
AO-128, alpha-glucosidase inhibitor: antiobesity and antidiabetic actions in genetically obese-diabetic rats, Wistar fatty.
Topics: Animals; Body Weight; Cyclohexanols; Diabetes Mellitus; Eating; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Male; Obesity; Rats; Rats, Wistar | 1995 |
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage].
Topics: Cerebral Hemorrhage; Cyclohexanols; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gait; Glycoside Hydrolase Inhibitors; Humans; Intestinal Obstruction; Middle Aged; Obesity | 1996 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptake Inhibitors; Obesity; Rats; Rats, Sprague-Dawley; Venlafaxine Hydrochloride | 1997 |
Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
Topics: Agoraphobia; Alcoholism; Cyclohexanols; Depressive Disorder; Female; Fructose; Hallucinations; Humans; Infarction, Posterior Cerebral Artery; Middle Aged; Neuroprotective Agents; Obesity; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Topiramate; Venlafaxine Hydrochloride | 2001 |
Delay of carbohydrate absorption by inhibitors of intestinal alpha-glucosidases.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Cyclohexanols; Dietary Carbohydrates; Gastric Mucosa; Insulin; Intestinal Absorption; Intestine, Large; Intestine, Small; Kinetics; Obesity; Oligosaccharides; Rats; Rats, Inbred Strains; Sucrose; Triglycerides; Trisaccharides | 1979 |
Antiobesity and antidiabetic actions of a new potent disaccharidase inhibitor in genetically obese-diabetic mice, KKA(y).
Topics: Animals; Blood Glucose; Cyclohexanols; Diabetes Mellitus, Experimental; Female; Glycoside Hydrolase Inhibitors; Intestine, Small; Kidney; Liver; Mice; Mice, Inbred Strains; Obesity; Sucrase | 1992 |
Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes.
Topics: Acarbose; Animals; Cyclohexanols; Diabetes Mellitus, Experimental; Disaccharidases; Glycoside Hydrolase Inhibitors; Intestines; Male; Obesity; Oligo-1,6-Glucosidase; Rats; Rats, Inbred Strains; Rats, Zucker; Sucrase; Trisaccharides | 1992 |
Treatment of visceral fat obesity.
Topics: 1-Deoxynojirimycin; Adipose Tissue; Animals; Cyclohexanols; Diet, Reducing; Disaccharides; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Obesity; Skin; Sucrase; Viscera | 1991 |
Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats.
Topics: Adipose Tissue; Animals; Cyclohexanols; Fatty Acids, Nonesterified; Female; Glycoside Hydrolase Inhibitors; Obesity; Rats; Rats, Zucker; Viscera | 1989 |
[The effect of an alpha-glucosidase inhibitor on fatty liver in obesity].
Topics: Administration, Oral; Animals; Cyclohexanols; Fatty Liver; Glycoside Hydrolase Inhibitors; Lipid Metabolism; Liver; Obesity; Rats; Rats, Zucker | 1987 |